Comparative Pharmacology
Head-to-head clinical analysis: LONITEN versus RAU SED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONITEN versus RAU SED.
LONITEN vs RAU-SED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arteries. It reduces peripheral vascular resistance and blood pressure by hyperpolarizing vascular smooth muscle cells via activation of ATP-sensitive potassium channels.
Reserpine depletes catecholamines (norepinephrine, dopamine) from adrenergic nerve endings by binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing neurotransmitter storage and leading to depletion of catecholamines.
10 mg orally twice daily, titrated to 40 mg twice daily for hypertension; for heart failure, start at 2.5-5 mg orally twice daily, max 20 mg twice daily.
Initial: 0.5 mg orally once daily; maintenance: 0.1-0.25 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 4.2 hours (range 3.5–5.5); clinically, half-life extends to 14–23 hours after chronic dosing due to drug accumulation.
Terminal elimination half-life: 45-90 hours (average 60 hours); clinical context: requires 5-7 days to reach steady-state; prolonged half-life may lead to cumulative effects
Renal: 85% (12% unchanged, 73% as glucuronide conjugates); biliary/fecal: 3%
Renal (60-70% as unchanged drug and metabolites); fecal (20-30% via biliary elimination)
Category C
Category C
Antihypertensive
Antihypertensive